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Introduction
AA amyloidosis may develop as a consequence of chronic
inflammatory conditions including autoinflammatory dis-
eases(AID). Mevalonate-kinase(MVK) deficiency(MKD)
appears to be the least frequent underlying condition
among monogenic periodic syndromes. Moreover, amy-
loidosis rarely manifests during childhood. We report a
case of a small child in whom renal biopsy performed
because of the cortico-resistant nephrotic syndrome
revealed amyloid A.
Objectives
To describe clinical manifestations, laboratory features





A 4-years old Caucasian girl with negative family history
presented with features of nephrotic syndrome in 1/
2011. Over the previous 2 years she has been suffering
with recurrent episodes of unexplained fever with phar-
yngitis and lymphadenitis lasting 3 days in 2-4 weekly
intervals and received a putative diagnosis of PFAPA
(periodic fever, adenitis, pharyngitis, aphtae) syndrome.
Despite the increasing frequency of febrile episodes over
the last year investigations aimed at excluding mono-
genic fevers were not performed. In early 2011 her IgD
was normal, IgA mildly elevated, serum amyoid A
(SAA) fluctuated from normal to 200 mg/l. After the
standard corticosteroid (CS) treatment of nephrotic syn-
drome had failed to induce remission after 6 wks, a
renal biopsy was performed revealing amyloid A depos-
its in about 30% glomeruli. While genetic analysis was
pending, Colchicine was added to the CS treatment fol-
lowed by daily anakinra injections with good clinical
response. After a laborious genetic screening to exclude
mutations causing monogenic AID, following heterozy-
gous variants in MVK gene were identified: Mutation
V377I and a novel deletion in exon 5 C152WfsX6
(c.450_453delGGTG). The latter terminates the protein
six amino acids after the deletion occurs, effectively
making the protein shorter. Within 6 months of the
treatment her proteinuria stabilised and there have been
no signs of other organ involvement. Despite ongoing
anakinra therapy she continues to have occasional feb-
rile episodes with temporary increase of inflammatory
parameters including SAA.
Conclusion
MKD/HyperIgD-syndrome has been so far reported in
only a few cases of AA-amyloidosis. Our patient has been
the youngest one to develop this severe complication. The
only other child reported so far was also a compound het-
erozygote carrying the genotype G326R/V377I. The long-
term follow-up with careful SAA serial measurements will
tell us more about the prognostic significance of the newly
described MVK gene deletion. This case report also
underlines the importance of careful differential diagnostic
re-evaluation of children presenting with PFAPA pheno-
type in whom febrile episodes do not show a typical
prolongation of afebrile intervals over the time.
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